Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 197787

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals
  • Gastrointestinal
  • HIV / AIDs
  • Pain
  • Veterinary
  • Respiratory
  • Bacterial Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 197787

License Grant
The agreement is for products containing crofelemer or any derivative thereof obtained from any species of the Croton lechleri plant.
License Property
The product is defined as all products for the treatment, maintenance or improvement of human health which are prescription medicines, botanicals, dietary supplements sold for the treatment of diarrhea, Irritable Bowel Syndrome (IBS) or herpes.
Field of Use
This agreement is for the pharmaceutical industry.

IPSCIO Record ID: 365949

License Grant
Licensor hereby grants to Italian Licensee
(a)  an exclusive (even as to Licensor), perpetual non-transferable license, with right to grant and authorize sublicenses solely under the Licensed IP and the Licensor Trademarks for Licensee to Develop and Commercialize Products in the Licensee Territory; and;  (b)  a non-exclusive, non-transferable license, with right to grant and authorize sublicenses (to a contract manufacturer only) solely under the Licensed IP for Licensee to Manufacture or have Manufactured Products for Commercialization in the Licensee Territory, including the right to Manufacture Crofelemer and Lechlemer; provided, however, that during the Term, Licensee shall only be entitled to utilize its license to Manufacture or have Manufactured Products to the extent provided.
License Property
Licensed Patents means collectively the Tier A Patents, the Tier B Patents for which Licensee has exercised its Tier B Option in accordance with this agreement and Tier C Patents for which Licensee has exercised its Tier C Option in accordance with this agreement.

US 8,962,680 – Methods and compositions for treating HIV-associated diarrhea
US 9,585,868 – Methods and compositions for treating HIV-associated diarrhea
US 8,846,113 – Method for treatment of diarrhea-predominant irritable bowel syndrome

Field of Use
Field of use is for the treatment of cancer, Irritable bowel syndrome and other diarrhea related conditions.

Crofelemer  is a naturally occurring botanical biopolymer extracted from the stem bark latex of the Croton lechleri tree. 1 It is an FDA-approved drug for the treatment of noninfectious diarrhea in adult patients with HIV/AIDS undergoing antiretroviral therapies and acts by inhibiting 2 chloride channels located in the gastrointestinal tract.

IPSCIO Record ID: 7614

License Grant
Licensor grants an exclusive, freely sublicensable and transferable license to use the Licensed Patent Rights, the Intellectual Property and the Technology to research, develop, formulate, make, have made, use, have used, market, offer for sale, sell, have sold, and import, and to otherwise exploit the Technology and Products.

Licensor may grant sublicenses of the licenses granted to Licensee in this Agreement to its Affiliates and Sublicensees.

License Property
The Technology shall mean all Licensor’s Compounds, formulations, and drug candidates, whether developed, in the process of development or in Licensor’s pipeline for development, including specifically, and without limitation,
(1) crofelemer (SP-303),
(2) normal stool formula (NSF),
(3) Nutraceutical (SB-300),
(4) any and all technology and information related to SP-303, NSF and SB-300, and any other product derived from, or containing an ingredient derived from, the crude plant latex of Croton lechleri owned by Licensor or to which Licensor had rights prior to July 1, 2005, NP-500,
(5) Licensor’s natural product pipeline of  tropical medicinal plants and extracts, and
(6) any and all technology and information related to Compounds, formulations, plants, and extracts,  including methods of isolating, manufacturing, formulating or otherwise manipulating the Compounds, formulations, plants and extracts for therapeutic use, and methods of use of such Compounds, formulations, plants, and extracts.

“Compound” shall mean any pharmaceutical, or biological product (including any over-the-counter product), any standardized botanical extract or nutraceutical substance or product, or any food or dietary supplement or other natural product currently marketed or in development or to be developed in the Field of Use, and subject to the terms of this Agreement.

Field of Use
Field of Use shall mean all veterinary treatment uses and indications for all species of animals except humans.

IPSCIO Record ID: 332244

License Grant
Licensor hereby grants to Licensee an exclusive (including with regard to Licensor and its Affiliates), royalty-bearing license, with the right to grant sublicenses in accordance with this Agreement, under the Licensor Technology, to Exploit the Licensed Compound or the Licensed Products in (a) the Human Excluding HIV/AIDS/ID/Pediatric Field in the Licensee Human Excluding HIV/AIDS/ID/Pediatric Territory; (b) the HIV/AIDS/Pediatric Field in the Licensee HIV/AIDS/Pediatric Territory; and (c) the ID Field in the Licensee ID Territory.

Licensor hereby grants to Licensee an exclusive (including with regard to Licensor and its Affiliates), royalty-bearing license and right of reference, with the right to grant sublicenses and further rights of reference in accordance with this Agreement, under the Regulatory Documentation Controlled by Licensor or any of its Affiliates, if any, to Exploit the Licensed Compound or the Licensed Products in (a) the Human Excluding HIV/AIDS/ID/Pediatric Field in the Licensee Human Excluding HIV/AIDS/ID/Pediatric Territory; (b) the HIV/AIDS/Pediatric Field in the Licensee HIV/AIDS/Pediatric Territory; and (c) the ID Field in the Licensee ID Territory.

Licensor hereby grants to Licensee a non-exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses in accordance with this Agreement, to use the Product Trademarks (to the extent Controlled by Licensor) as necessary to exercise its rights under the grants in this Agreement, provided that Licensor shall have a right to monitor and comment upon the manner in which such Product Trademarks are used.

License Property
Licensed Compound means oligomeric proanthocyanidin (OPC) of varying chain lengths with an average molecular weight of approximately 2000 daltons (Crofelemer), including any Improvements thereto.

Licensed Product means any form or dosage of pharmaceutical composition or preparation in finished form labeled and packaged for sale by prescription, over-the-counter, dietary supplement, food or any other method that contains the Licensed Compound as an active ingredient (including a Licensed Product that contains the Licensed Compound as an active ingredient together with one or more other active ingredients (which may be either combined in a single formulation or bundled with separate formulations but sold as one product)), and any Improvements thereto.

Patents
5,211,944 – Proanthocyanidin polymers having antiviral activity and methods of obtaining same
5,494,661 – Methods for using proanthocyanidin polymers having antiviral activity
7,341,744 – Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer

Product Trademarks shall mean all Trademarks for use with a Licensed Product designated in accordance with this Agreement and any registrations thereof or any pending applications relating thereto.

Trademark shall include any word, name, symbol, color, designation or device or any combination thereof, including any trademark, trade dress, brand mark, trade name, brand name, logo or business symbol, which in each case is specific to a Licensed Product. Notwithstanding anything in the foregoing, the term “Trademark” does not include any house marks, trade dress or logos of Licensee or its Affiliates.

Field of Use
Licensee is investigating crofelemer in a Phase III study as an anti-secretory anti-diarrheal agent for the treatment of chronic diarrhea in people living with HIV, or HIV-associated diarrhea

Human Excluding HIV/AIDS/ID/Pediatric Field means all indications of the Licensed Compound for human use or consumption (including by way of food or dietary supplements), other than HIV/AIDS-related diarrhea, acute infectious diarrhea and pediatric diarrhea of any etiology including cholera; HIV/AIDS/Pediatric Field means only those indications of the Licensed Compound for human use for HIV/AIDS-related diarrhea and pediatric diarrhea; and ID Field means only those indications of the Licensed Compound for human use for acute infectious diarrhea, specifically including cholera and traveler’s diarrhea. This also includes the ID Field and the  HIV/AIDS/Pediatric Field.

IPSCIO Record ID: 266736

License Grant
Licensor, a non-profit hospital, grants to Licensee to the extent of the Licensed Territory an exclusive license under the patent rights to make, have made, use, sell and have sold, and import licensed products in the Licensed Field, with the right to sub license.

Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.

License Property
Licensor owns US Patent application for Methods of Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth, and, US Patent entitled Methods of Diagnosing or Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth.

Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.

Field of Use
Rifaximin is an antibiotic used to treat traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy.

IPSCIO Record ID: 2810

License Grant
Licensor grants an exclusive license to make, have made, use or sell for use in the Field within the United States and its territories (Puerto Rico, Guam), Canada and Mexico.  The Compound and Product pursuant to all Licensor’s Intellectual Property Rights.
License Property
Licensor has discovered a compound internally designated as LY315535 (5,434,174) which may be useful in the treatment of functional gastrointestinal disorders and other indications.

Compound means 2-di-n-propylamino-8-(isoxazol-5-yl)-1,2,3,4-tetrahydronaphthalene and all pharmaceutically acceptable salts and solvates.

Field of Use
Field means products for Gastrointestinal Indications.  
Gastrointestinal Indications means disease states, such as excess gastric acid secretion, inflammatory bowel disease, irritable bowel syndrome, gastroesophagael reflux disease, esophagitis, dyspepsia, proctitis, hemorrhoids, gastrointestinal ulceration, nausea and vomiting and constipation and diarrhea, which are characterized by abnormalities of the Digestive System, regardless of the mechanism involved in such disease states.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.